

ExpreS2ion Hereby Changes Certified Advisor to Redeye

Hørsholm, Denmark, 7 November 2025 – ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") today announces it has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on February 1, 2026. Until then, Svensk Kapitalmarknadsgranskning AB will continue as Certified Adviser to the company.

The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

About ExpreS2ion

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO

Keith Alexander, CFO

Email: investor@expres2ionbio.com